Benjamin Hohl, CHIEF FINANCIAL OFFICER at Enliven Therapeutics, Inc. (ELVN), sold 6,018 shares at $50.03 ($303K) on 2026-09-17, disclosed to the SEC on 2026-09-21.
Scheduled sale ($303k) by CHIEF FINANCIAL OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $50.03 | 3,535 | $177K | 58.4% |
| 2 | $50.72 | 2,194 | $111K | 36.7% |
| 3 | $51.49 | 289 | $15K | 4.9% |
| Total | $50.35 avg | 6,018 | $303K | 100% |
| Filing → |
| ELVN | SELL | 2026-06-22 | $264K | — | Filing → |
| ELVN | SELL | 2026-03-10 | $296K | — | Filing → |
| ELVN | SELL | 2025-10-01 | $66K | — | Filing → |